An Indirect Treatment Comparison of Lenvatinib for the First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma.

Adv Ther · 2025 · PMC11787224 · PMID 39680315

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although lenvatinib plus pembrolizumab was found to show improvement in OS and progression-free survival (PFS) vs lenvatinib monotherapy, these results did not reach statistical significance [ 14 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.